Form 4 Jazz Pharmaceuticals For: Aug 08 Filed by: ENRIGHT PATRICK G
Last jazz pharmaceuticals plc earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com
| Impact snapshot | Event time: | JAZZ | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
JAZZ alerts
JAZZ alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals Plc news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/JAZZ/price-target/">NASDAQ: JAZZ</a>) had its price target raised by analysts at Stifel Nicolaus from $195.00 to $202.00. They now have a "buy" rating on the stocMarketBeat
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic HypersomniaPR Newswire
- Jazz Pharmaceuticals plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/JAZZ/price-target/">NASDAQ: JAZZ</a>) had its price target raised by analysts at Morgan Stanley from $162.00 to $176.00. They now have an "equal weight" rating onMarketBeat
- Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric PatientsPR Newswire
- Jazz Pharmaceuticals plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/JAZZ/price-target/">NASDAQ: JAZZ</a>) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating.MarketBeat
- More
JAZZ
SEC Filings
- 4/7/21 - Form 4
- 4/6/21 - Form 4
- 3/23/21 - Form 8-K
- JAZZ's page on the SEC website
- More